Baixar PDF

Outros usuários também visualizaram estes artigos

TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES NWCJV Donk; R Popat; L Rosiol; B Besemer; JM Lopez; D Trancucci; R Verona; T Stephenson; K Chastain; N Bahlis;
Hematol Transfus Cell Ther. 2023;45 Supl 4:S397-8
CILTACABTAGENE AUTOLEUCEL VS STANDARD OF CARE IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: PHASE 3 CARTITUDE-4 SUBGROUP ANALYSIS BY CYTOGENETIC RISK R Mina; B Dhakal; J San-Miguel; N Lendvai; M Vogel; K Li; D Chen; N Patel; H Einsele; J Martinez-Lopez;
Hematol Transfus Cell Ther. 2024;46 Supl 4:S533-4
EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN¿DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES A Nooka; A Lesokhin; M Mohty; R Niesvizky; C Maisel; B Arnulf; S Larson; A Varshavsky-Yanovsky; X Leleu; L Karlin; D Vesole; N Bahlis; CF Larrea; N Raje; E Leip; U Conte; M Elmeliegy; A Viqueira; V Blunk; S Manier;
Hematol Transfus Cell Ther. 2023;45 Supl 4:S405